Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Senzime AB ( (SE:SEZI) ) is now available.
Senzime AB has secured a significant contract with a major U.S. university hospital system to supply its TetraGraph monitors and engage in scientific collaboration. This agreement, which involves the installation of 63 monitors in Texas, aims to standardize neuromuscular monitoring for over 27,000 patients annually. The collaboration will leverage Senzime’s TetraConnect platform and AI analysis to enhance anesthesia care through personalized, data-driven approaches. This milestone not only represents one of Senzime’s largest installations but also sets a benchmark for implementing Quality Improvement initiatives in anesthesiology, potentially transforming patient monitoring and management during surgery.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety and outcomes. Their flagship product, the TetraGraph system, is widely used for neuromuscular monitoring during surgery and is aligned with recent clinical guidelines. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 327,027
Current Market Cap: SEK799.8M
See more insights into SEZI stock on TipRanks’ Stock Analysis page.